Loading...
•
Dec 28, 2024
Haemonetics Q3 2025 Earnings Report
Haemonetics reported third quarter of fiscal year 2025 results and updated fiscal year 2025 guidance.
Key Takeaways
Haemonetics reported a 3.7% increase in revenue compared to the third quarter of fiscal 2024, with a notable 23.9% growth in the Hospital business unit. The company's adjusted earnings per diluted share increased by 14.4% to $1.19, and cash on hand increased by $142.0 million since the end of fiscal 2024.
Third quarter fiscal 2025 revenue was $348.5 million, up 3.7% compared with the third quarter of fiscal 2024.
Earnings per diluted share were $0.74, compared to $0.61 in the same period last year.
Adjusted earnings per diluted share reached $1.19, a 14.4% increase year-over-year.
Cash flow from operating activities was $43.8 million, with free cash flow at $29.6 million.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company updated its fiscal 2025 GAAP total revenue and organic revenue growth guidance. Adjusted operating margin is expected to be ~24%. Adjusted earnings per diluted share are projected to be $4.50 - $4.70. Free cash flow is anticipated to be $120M - $140M.
Positive Outlook
- Total Company Reported Revenue growth is guided between 3-5%.
- Hospital Reported Revenue growth is guided at 24-26%.
- Adjusted operating margin is expected to be ~24%.
- Adjusted earnings per diluted share are projected to be $4.50 - $4.70.
- Focus on sustained long-term growth across the business.
Challenges Ahead
- Plasma Reported Revenue growth is guided between -5% to -7%.
- Blood Center Reported Revenue growth is guided between -7% to -9%.
- Organic growth is guided between 0-3%.
- Free cash flow is anticipated to be $120M - $140M, lower than previous guidance.
- External market challenges are still present.
Revenue & Expenses
Visualization of income flow from segment revenue to net income